These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 27286500)

  • 1. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.
    Ferrer M; Boccon-Gibod I; Gonçalo M; İnalöz HS; Knulst A; Lapeere H; Parthasaradhi A; Stingl G; Tagka A; Valenzuela F; Yeung J; Thomsen SF
    Eur J Dermatol; 2017 Oct; 27(5):455-463. PubMed ID: 29084635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab in Chronic Urticaria: An Italian Survey.
    Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
    Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab.
    Spertino J; Curto Barredo L; Rozas Muñoz E; Figueras Nart I; Gimenez Arnau A; Serra Baldrich E; Bonfill-Ortí M; Expósito-Serrano V; Guilabert A; Melé Ninot G; Villar Buil M; Garcias Ladaria J; García Navarro X; Vilavella M; Bielsa Marsol I; Aparicio Ortiz G; Baliu Piqué C; Álvarez Abella A; Lamas Domenech N; Mascaró JM; Gómez S; Torné Gutiérrez JI; Vicente Villa A; Gimenez Arnau A
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):771-776. PubMed ID: 30107875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
    Sánchez J; Zakzuk J; Cardona R
    J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
    Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
    Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria.
    Syrigos N; Grapsa D; Zande M; Tziotou M; Syrigou E
    Int J Dermatol; 2018 Apr; 57(4):417-422. PubMed ID: 29399789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
    Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
    J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab: what benefits should we expect?
    Giménez-Arnau A; Velasco M; Armario Hita JC; Labrador-Horrillo M; Silvestre Salvador JF
    Eur J Dermatol; 2016 Aug; 26(4):340-4. PubMed ID: 27210073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.